GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Posted: 27 July 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk…
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial…
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company…
New WEHI spinout company tackles hard-to-treat cancers
Posted: 20 June 2024 A new WEHI spinout company launched this week will use a world-leading technology to target cancers that are difficult to treat with existing medicines. In 2023, the Albanese Government awarded $15 million in funding…
Forbes Australia recognises Professor Mimi Tang as an entrepreneur to watch
Posted: 20 June 2024 Professor Mimi Tang, Scientific Founder and CEO, Prota Therapeutics has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen…
King’s Birthday Honours for contributions in research, education and public health
Posted: 14 June 2024 Victoria’s remarkable talent shines bright in this year’s King’s Birthday Honours, including nine leaders from BioMelbourne Network member organisations – AusBiotech,…
A$7M Placement Plus SPP to Advance Development and Commercialisation of Proprietary Research Tools, Diagnostics and Therapeutics
Posted: 13 June 2024 Highlights: INOVIQ successfully completed a A$7 million placement to institutional and sophisticated investors at A$0.50 per share. INOVIQ Board and Management have participated in the placement. Funds raised will be used to advance commercialisation…
Cartherics Secures Australian Patent for Innovative Cancer Cell Therapy
Posted: 12 June 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically…
ACPCC begins HPV self-collection campaign to providers
Posted: 4 June 2024 The Australian Centre for the Prevention of Cervical Cancer is pleased to announce that they have received government funding to undertake a nationwide healthcare provider education campaign about supporting patient choice in cervical…
Breakthrough exosome therapy to target and kill breast cancer
Posted: 4 June 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully produced and isolated engineered exosomes (EEVs) that target and kill breast cancer cells in vitro. In a proof-of-concept study, a breast…
MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus
Posted: 4 June 2024 Murdoch Children’s Research Institute (MCRI) and Incepta Pharmaceuticals, based in Bangladesh, have embarked on a collaboration aimed at bringing life-saving innovation to the global healthcare landscape. MCRI has announced the signing of a non-exclusive licensing…
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Posted: 4 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that it has entered into a clinical trial collaboration and…
